# Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma

> **NCT01534585** · PHASE1,PHASE2 · COMPLETED · sponsor: **Taizhou Hospital** · enrollment: 48 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Icotinib
- **RADIATION:** intensity-modulated radiotherapy
- **DRUG:** Paclitaxel and Cisplatin
- **OTHER:** Quality of life
- **GENETIC:** Epidermal growth factor receptor status

## Key facts

- **NCT ID:** NCT01534585
- **Lead sponsor:** Taizhou Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2013-02
- **Final completion:** 2015-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2018-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01534585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01534585, "Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01534585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*